Articlenpj drug discovery2026
Prioritizing neuroactive ligands using motif-guided virtual discovery and zebrafish profiling.
Article in npj drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
9 authors.
Funding
Abstract
Virtual screening of ultra-large chemical libraries is a highly effective strategy for early-stage ligand discovery. However, these pipelines often yield thousands of molecules that pass computational filters, and in silico-derived interaction energies do not consistently predict experimental efficacy. Furthermore, many high-affinity hits do not necessarily function effectively in an organism with tissues, barriers, and extensive off-target possibilities. Here, we establish and apply an integrated pipeline that prioritizes candidate molecules through structure-guided computation and zebrafish-based functional profiling. We introduce Rosetta Engine for Anchoring Ligands with a Motif ("REAL-M"), a screening algorithm that uses structural interaction data from the Protein Data Bank (PDB) to guide ligand placement and selection. Using the hypocretin receptor as a test case, 28 of 30 predicted antagonists significantly blocked binding of the cognate peptide agonist in a cell-based reporter assay, including six chemically diverse molecules with efficacy comparable to preexisting antagonists. Three of these six significantly mitigated hypocretin-induced larval zebrafish hyperactivity. Secondary testing with a zebrafish hcrtr2 null mutant ensured that behavioral phenotypes were on target, in contrast to off-target phenotypes observed with a clinically approved antagonist. This pipeline is readily adaptable to the thousands of zebrafish proteins with highly conserved binding pockets.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.